Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SHR-3167 vs insulin degludec in type 2 diabetes mellitus
CTR20252232Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-3167 in type 2 diabetes mellitus (T2DM), sponsored by Hengrui Therapeutics. Started Jul 2025; status: active.
02
Drugs
SHR-3167
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20252232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252232.